StreetInsider.com News Articles

Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.

Wed, 29 Oct 2025 21:00:00 -0400

BEIJING, Oct. 29, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes and challenging cases of JensClip and Ken-Valve, a proprietary TMVr system and TAVR (AR) system respectively, representing

Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.

Wed, 29 Oct 2025 21:00:00 -0400

Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.

Wed, 29 Oct 2025 21:00:00 -0400

Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.

Wed, 29 Oct 2025 21:00:00 -0400

Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.

Wed, 29 Oct 2025 21:00:00 -0400

Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.

Wed, 29 Oct 2025 21:00:00 -0400

Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.

Wed, 29 Oct 2025 21:00:00 -0400

Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.

Wed, 29 Oct 2025 21:00:00 -0400

LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect

Thu, 09 Oct 2025 09:00:00 -0400

BEIJING, Oct. 9, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with comprehensive structural heart disease interventional solutions, recently announced that LuX-Valve Plus transjugular tricuspid valve replacement system, the product of its subsidiary Jenscare Scientific (Netherlands) B.V., has been officially approved to be included

LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect

Thu, 09 Oct 2025 09:00:00 -0400

LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect

Thu, 09 Oct 2025 09:00:00 -0400

LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect

Thu, 09 Oct 2025 09:00:00 -0400

LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect

Thu, 09 Oct 2025 09:00:00 -0400

LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect

Thu, 09 Oct 2025 09:00:00 -0400

LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect

Thu, 09 Oct 2025 09:00:00 -0400

LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect

Thu, 09 Oct 2025 09:00:00 -0400

Jenscare, releases 2025H1 interim results

Mon, 01 Sep 2025 01:00:00 -0400

BEIJING, Sept. 1, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with TTVR breakthroughs, achieved milestones in its product portfolio globally, and just released its interim results for 2025H1 ended June 30, 2025.

Business Overviews:

In 2025H1, significant progress was achieved across its product pipeline in the interventional treatment for tricuspid, aortic and mitral valve diseases, establishing a diversified and high-potential product portfolio. More importantly, the Company continued to expand its global business layout, enhancing product influence and clinical

Jenscare, releases 2025H1 interim results

Mon, 01 Sep 2025 01:00:00 -0400

Business Overviews:

Jenscare, releases 2025H1 interim results

Mon, 01 Sep 2025 01:00:00 -0400

Business Overviews:

Jenscare, releases 2025H1 interim results

Mon, 01 Sep 2025 01:00:00 -0400

Business Overviews:

Jenscare Announces 2025H1 Interim Results

Sun, 31 Aug 2025 21:00:00 -0400

BEIJING, Aug. 31, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases, achieved key milestones in its product portfolio and just announced its interim results for 2025H1.

Business Highlights: Big Movement in Commercialization, Registration and Clinical

LuX-Valve Series, TTVR system

In China, the multicenter clinical trial for NMPA approval has entered long-term follow-up phase, demonstrating excellent results. The randomized controlled trial (RCT) of optimized medical therapy (OMT) has completed subject enrollment. The registration

Jenscare Announces 2025H1 Interim Results

Sun, 31 Aug 2025 21:00:00 -0400

Business Highlights: Big Movement in Commercialization, Registration and Clinical

LuX-Valve Series, TTVR system

In China, the multicenter clinical trial for NMPA approval has entered long-term follow-up phase, demonstrating excellent results. The randomized controlled trial (RCT) of optimized medical therapy (OMT) has completed subject enrollment. The registration

Jenscare Announces 2025H1 Interim Results

Sun, 31 Aug 2025 21:00:00 -0400

Business Highlights: Big Movement in Commercialization, Registration and Clinical

LuX-Valve Series, TTVR system

In China, the multicenter clinical trial for NMPA approval has entered long-term follow-up phase, demonstrating excellent results. The randomized controlled trial (RCT) of optimized medical therapy (OMT) has completed subject enrollment. The registration

Jenscare Announces 2025H1 Interim Results

Sun, 31 Aug 2025 21:00:00 -0400

Business Highlights: Big Movement in Commercialization, Registration and Clinical

LuX-Valve Series, TTVR system

In China, the multicenter clinical trial for NMPA approval has entered long-term follow-up phase, demonstrating excellent results. The randomized controlled trial (RCT) of optimized medical therapy (OMT) has completed subject enrollment. The registration

Jenscare released 30-day follow-up results of LuX-Valve Plus TRINITY study and 1-year follow-up results of JensClip TMVr at EuroPCR 2025

Mon, 02 Jun 2025 21:00:00 -0400

BEIJING, June 2, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes of JensClip, a proprietary TMVr system, at EuroPCR 2025 in Paris, France.

30-Day Follow-up Results of LuX-Valve Plus TRINITY Study

TRINITY is a global prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid regurgitation and